Clinical Trial Detail

NCT ID NCT02640209
Title Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL)
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors University of Pennsylvania
Indications

CLL/SLL

Therapies

CART19 cells

Age Groups: adult senior

No variant requirements are available.